Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 682217
                    [Title] => Roche drug for treating systemic juvenile  idiopathic arthritis gets US FDA approval
                    [Summary] => 
The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.
                    [DatePublished] => 2011-05-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 590859
                    [Title] => New hope for children with systemic juvenile idiopathic arthritis
                    [Summary] => 
Roche announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that Actemra is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
                    [DatePublished] => 2010-07-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

SJIA

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 682217
                    [Title] => Roche drug for treating systemic juvenile  idiopathic arthritis gets US FDA approval
                    [Summary] => 
The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.
                    [DatePublished] => 2011-05-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 590859
                    [Title] => New hope for children with systemic juvenile idiopathic arthritis
                    [Summary] => 
Roche announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that Actemra is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
                    [DatePublished] => 2010-07-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche drug for treating systemic juvenile idiopathic arthritis gets US FDA approval

May 5, 2011 - 12:00am

The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.

Science and Environment

New hope for children with systemic juvenile idiopathic arthritis

July 8, 2010 - 12:00am

Roche announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that Actemra is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic...

Science and Environment